Bringing the fundamentals into focus…
Back to Xeris Biopharma Holdings, Inc.
How Xeris Biopharma Holdings, Inc. stacks up
XERS · against 428 other Healthcare companies of similar size
Valuation
36/ 100
Below the middle of the pack.
Ranked #286 of 429 · scores higher than 32% of peers
Bars: peers in each 10-point band of the valuation score33 peers with a valuation score of 30–39, including XERS · Click a bar to see the companies
Why valuation scores 36?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -0.9% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 1.9% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 67% of peers. Free cash flow yield: 3.0% vs peer median 0.0%
Metric by metric
Position: dot = XERS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | XERS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 416 reported | -1.0% | 1.7% | 37% | 30% | |
| EBITDA yieldHigher is better · 428 reported | 2.4% | 4.5% | 39% | 50% | |
| Free cash flow yieldHigher is better · 194 reported | 3.0% | -0.5% | 66% | 20% | |
| Book yieldHigher is better · 418 reported | -0.5% | 35.7% | 4% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around XERS| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 286 | 18.7B CNY (≈$2.6B) | 36 | 51 | |
| 286 | 1.2B CHF (≈$1.4B) | 36 | 34 | |
| 286 | 1.2B USD | 36 | 36 | |
| 286 | 3.1B USD | 36 | 53 | |
| 286 | 1.9B USD | 36 | 47 | |
| 291 | 1.2B USD | 33 | ||
| 291 | 2.2B USD | 33 | 48 | |
| 291 | 1.8B USD | 33 | ||
| 291 | 3.3B USD | 33 | 39 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score